Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Rectal Neoplasms 1Melanoma 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

fluciclovine F-18 2Positron-Emission Tomography 2Injections 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2pembrolizumab 1ioflupane 1idelalisib 1aflibercept 1Water 1Vertical Dimension 1Methylene Blue 1Mammography 1Drug Delivery Systems 1Diagnosis, Computer-Assisted 1Daunorubicin 1Cytarabine 1Control Groups 1CPX-351 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Disease × Diagnosis, Computer-Assisted × Clear all
NCT06221397 2026-03-16

LEGIT_MC_EVCDA

AI Labs Group S.L

Completed
105 enrolled 15 charts
Dermatologic

Disease, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡